TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Valsartan on Left Ventricular Myocardial Functions in Hypertensive Patients With Left Ventricular Hypertrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* hypertension with left ventricular hypertrophy~Exclusion Criteria:~* clinical or laboratory evidence of secondary hypertension~* heart failure~* ischemic heart disease~* valvular heart disease~* arrhythmias~* peripheral vascular disease~* chronic obstructive pulmonary disease~* neurologic disorders~* diabetes mellitus~* renal dysfunction~* notable systemic disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Valsartan treatment (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Prevnar 13 on Ear Infections in Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject has received full (3-dose) infant series of Prevnar 13~Exclusion Criteria:~* Prior vaccination with any 7vPnC.~* Prior vaccination with 23-valent pneumococcal polysaccharide vaccine (23vPS).~* Any major illness/condition that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in the study.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 30 Months
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Integrating Clinical Practice Guidelines for Smoking Cessation Into Mental Health Care for Veterans With Posttraumatic Stress Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Receive a minimum of four mental health treatment sessions from the SOPP that span at least a 1-month interval~* SOPP treatment plan must indicate intent to deliver ongoing PTSD care for at least 1 year, including visits at least once per month~* Diagnosis of PTSD resulting from military trauma using DSM-IV criteria~* Current nicotine use, smoking greater at least 10 cigarettes per day for at least 16 of the past 30 days prior to randomization~* Demonstrated motivation to quit smoking~Exclusion Criteria:~* Use of smokeless tobacco or smoke pipes or cigars~* Any psychotic disorder that is not in remission~* Bipolar disorder that is not in remission~* Any substance dependence disorder that is not in remission (current substance abuse disorder and substance dependence disorder in remission for more than 1 month are not exclusions)~* Imminent risk for suicide or violence, as determined during routine assessment by SOPP clinical staff~* Severe psychiatric symptoms or psychosocial instability likely to prevent participation in the study protocol (i.e., attendance at scheduled sessions, ability to read study materials, and/or ability to comprehend interventions), as determined during routine assessment by SOPP clinical staff~* Gross impairment from organic mental disorder, as determined during routine assessment by SOPP clinical staff

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Integration of smoking cessation therapy with PTSD therapy.
- Arm 2 (Type: ACTIVE_COMPARATOR): Per standard of care, patients are referred to a smoking cessation clinic for their smoking cessation therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants had given written informed consent to participate in the study in accordance with local regulations~* Adult participants 18 years and older with a diagnosis of T1DM made at least 1 year prior to informed consent~* Participants were being treated with insulin or insulin analog~* Willing and able to perform self-monitoring of blood glucose (SMBG) and complete the study diary as required per protocol~* At the Screening Visit, A1C was between 7.0% to 11.0%~* Females of childbearing potential used an adequate method of contraception and had a negative pregnancy test~Exclusion Criteria:~* Use of antidiabetic agent other than insulin or insulin analog at the time of screening~* Use of sodium-glucose cotransporter (SGLT) inhibitors within 8 weeks prior to screening~* Chronic systemic corticosteroid use~* Type 2 diabetes mellitus (T2DM), or severely uncontrolled T1D as determined by the Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Two placebo-matching to sotagliflozin tablets daily, orally, before the first meal of the day for 24 weeks.
- Sotagliflozin 400 mg (Type: EXPERIMENTAL): Sotagliflozin 400 milligram (mg) (two 200 mg tablets) once daily, orally, before the first meal of the day for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Short-course Antimicrobial Therapy for Paediatric Respiratory Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Children aged 6 months to 10 years presenting with CAP will be eligible. CAP will be defined if all of the four following numeric criteria are met:~1. fever (\>37.5 C axillary, \> 37.7 C oral, or \>38 C rectal) recorded in the ED or at home in the 48h prior to presentation;~2. any one of:~   1. tachypnoea on exam (\>60 bpm for age \<1 y, \>50 bpm for 1-2 y of age, \>40 bpm for 2-4 y of age, and \>30 bpm for \>4 y of age);~  2. cough on exam or by history;~  3. increased work of breathing on exam; or~  4. auscultatory findings (focal crackles, bronchial breathing, etc.) consistent with pneumonia;~3. infiltrates on chest radiograph consistent with bacterial CAP as judged by the ED physician; and~4. the attending ED physician diagnoses the child with primary CAP. (Children treated with systemic steroids in the ED will be presumed to have primary asthma exacerbation with possible infection and therefore will not meet inclusion criteria.)~Participants must be well enough to be treated as outpatients (discharged home by the ED physician, adequate volume status, able to tolerate oral medication, oxygen saturation \> 90%, no evidence of impending respiratory failure), and have no evidence of empyaema or necrotizing pneumonia on chest radiograph.~Exclusion Criteria:~Children will be excluded if they have any of the following: cystic fibrosis, anatomic lung disease, bronchiectasis, congenital heart disease, history of repeated aspiration or velopharyngeal incompetence, malignancy, conditions requiring treatment with immune suppressants, primary immunodeficiency, advanced HIV infection, prolonged admissions (\>48 h) to hospital within the past 2 months, pneumonia previously diagnosed within the past month, lung abscess diagnosed within the past six months, receipt of \> 24 hours of beta-lactam antibiotic therapy already received at presentation to the ED, receipt of at least a 5 day course of amoxicillin \< 72h prior to presenting to the ED, receipt of an intravenous cephalosporin or azithromycin in the ED, or suspected allergy to penicillin. Children will not be eligible to participate more than once.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- Short-course (Type: EXPERIMENTAL): 5 days amoxicillin 90 mg/kg/day divided TID followed by 5 days placebo TID
- Standard (Type: ACTIVE_COMPARATOR): 5 days amoxicillin 90 mg/kg/day divided TID followed by alternate formulation 5 days amoxicillin 90 mg/kg/day divided TID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Test 2 Doses of the HRV Vaccine Given With or Without OPV in Healthy Infants in Bangladesh

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Healthy infants aged 6 weeks±1 at first study vaccination.~Exclusion criteria:~* Malnutrition, no history of rotavirus gastroenteritis, allergic disease or chronic gastrointestinal disease, not received protocol-prohibited treatment.

- Gender: ALL
- Minimum Age: 5 Weeks
- Maximum Age: 7 Weeks
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May Experience

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Provide informed consent~* History of GERD with persistent symptoms despite treatment with PPI~* Otherwise normal physical health~Exclusion Criteria:~* History of GERD with symptoms that has not improved at all during treatment with PPI~* Prior surgery of the upper gastrointestinal tract~* History of significant heart disease, cardiovascular, respiratory, hepatic, renal, metabolic, psychiatric or gastrointestinal disorders besides GERD

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): AZD3355 30 mg
- B (Type: EXPERIMENTAL): AZD3355 90 mg
- C (Type: EXPERIMENTAL): AZD3355 120 mg
- D (Type: EXPERIMENTAL): AZD3355 240 mg
- E (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of Darbepoetin Alfa Extended Dosing

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Greater than or equal to 18 years of age~* CRI with a creatinine clearance of greater than 15 but less than 40 mL/min~* Stable once every other week darbepoetin alfa SC for at least 6 weeks~* Hb values during screening / baseline of 10.0 - 12.0 g/dL~* Serum B12 and folate levels above the lower limit of normal and iron replete~Exclusion Criteria:~* Receiving renal replacement therapy~* Uncontrolled hypertension~* Hyperparathyroidism~* Major surgery, active inflammatory disease, receiving antibiotics, HIV-positive~* Current malignancy~* Pregnant or breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- darbepoetin alfa (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gaming for Autism to Mold Executive Skills Project

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children should be 7 to 11 years of age~* Children must have a parent/guardian who is available and willing to provide informed consent and to respond to screening phone calls~* Children should have an existing diagnosis of an autism spectrum disorder, which will be confirmed using research measures and criteria~* Children must have general cognitive ability in the average range or above (above 80 using the Wechsler Abbreviated Scale of Intelligence-2 Full Scale IQ)~* Caregivers and children must be fluent in English~Exclusion Criteria:~* Children must not have a seizure disorder or be taking medication that alters EEG processes (e.g. anti-seizure medications)~* Children must not have medical disorders or injuries affecting the brain or spinal cord~* Children may not have experienced significant prenatal exposure to substances such as tobacco, alcohol or street drugs~* Children may not have significant sensory or motor impairment that would limit the ability to participate in table top or EEG testing, or make responding during computer activities difficult

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Training (Type: EXPERIMENTAL): Computerized executive control training
- Waitlist (Type: NO_INTERVENTION): The waitlist group will not initially receive the training program. At the end of the study, the waitlist group will be offered training if it is efficacious.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Intra-abdominal Pressure to the Level of the Sensory Block at Caesarean Section Under Spinal Anesthesia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Gestational age 36 - 40 weeks~* Singleton pregnancies~* Elective caesarean section~Exclusion Criteria:~* Gestational age \<= 35 weeks~* Twins pregnancies~* Disease the cardiovascular system (hypertension, etc.)~* Non-elective caesarean section

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Measurement of IAP (Type: EXPERIMENTAL): The data obtained are in inches of water column were translated in millimeters of mercury.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Denmark and Sweden, as Part of Local Clinical Practice (SURE DENMARK/SWEDEN)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria: - Signed informed consent obtained before any study-related activities (study-related activities are any procedures related to recording of data according to protocol) - The decision to initiate treatment with commercially available semaglutide has been made by the patient/Legally Acceptable Representative and the treating physician before and independently from the decision to include the patient in this study - Male or female, age greater than or equal to 18 years at the time of signing informed consent - Diagnosed with type 2 diabetes at least 12 weeks prior to inclusion -Available and documented haemoglobin A1c (HbA1c) value less than or equal to 12 weeks prior to initiation of semaglutide treatment Exclusion Criteria: - Previous participation in this study. Participation is defined as having given informed consent in this study - Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation - Treatment with any investigational drug within 90 days prior to enrolment into the study - Hypersensitivity to semaglutide or to any of the excipients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semaglutide (Type: None): Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has a positive history of ocular allergies and a positive skin test reaction to a perennial allergen and a seasonal allergen~* Has a positive bilateral CAC reaction to a perennial allergen within minutes of instillation~Exclusion Criteria:~* History of refractive surgery (including LASIK procedures) within the past 2 years~* History of retinal detachment, diabetic retinopathy, or active retinal disease~* Presence of an active ocular infection or positive history of an ocular herpetic infection at any visit~* History of IOP increase as a result of steroid treatment~* A female who is currently pregnant, planning a pregnancy, or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OTX-DP (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male/female from 16 to 65 years~* Well-characterized focal epilepsy or epileptic syndrome according to the International League Against Epilepsy (ILAE) classification~* History of partial onset seizures~* Subjects having at least 4 partial onset seizures during the 4-week Baseline Period and at least 2 partial onset seizures during the 3 months prior to Visit 1~* Subjects taking 1 or 2 concomitant Antiepileptic drugs (AED(s)) that have been at a stable dose.~Exclusion Criteria:~* Seizure type IA non-motor as only seizure type~* Seizures occurring only in clusters~* Status epilepticus during the last 2 years before Visit 1~* History of cerebrovascular accident (CVA)~* Presence of any sign suggesting rapidly progressing brain disorder or brain tumor

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Matching Placebo tablets administered twice a day
- Brivaracetam 5 mg/day (Type: EXPERIMENTAL): Brivaracetam 5 mg/day, 2.5 mg administered twice a day
- Brivaracetam 20 mg/day (Type: EXPERIMENTAL): Brivaracetam 20 mg/day, 10 mg administered twice a day
- Brivaracetam 50 mg/day (Type: EXPERIMENTAL): Brivaracetam 50 mg/day, 25 mg administered twice a day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: N-methylglycine (Sarcosine) Treatment for Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18-55 years~* Fulfilled the DSM-IV criteria of major depressive disorder~* Had a 17-item Hamilton Rating Scale for Depression (HAMD-17)\>or= 18~* No DSM-IV diagnosis of substance abuse or dependence (including alcohol) within the past 6 months~* Had been drug free for \> 3 months~* Physically healthy and had all laboratory parameters within normal limits.~* Agree to participate in the study and provide informed consent~Exclusion Criteria:~* Had history of epilepsy, head trauma or other major neurological or medical diseases~* Had psychotic depression, bipolar I/II disorder, schizophrenia or any other psychotic disorder~* Moderate-severe suicidal risks~* Severe cognitive impairment~* Female subjects who were pregnant, or at risk of pregnancy or lactation~* Initiating or stopping formal psychotherapy within six weeks prior to enrollment~* Had a history of poor response to SSRIs or previously received electroconvulsive therapy~* Had a history of severe adverse reaction to SSRIs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- sarcosine (Type: EXPERIMENTAL): sarcosine
- citalopram (Type: ACTIVE_COMPARATOR): citalopram

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Dysport RU and Glabellar Lines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Female between 30 - 60 years of age~* Moderate to severe vertical glabellar lines at maximum frown at baseline~Exclusion Criteria:~* Silicone injections into the upper face~* Any prior treatment with fillers (e.g. collagen-type implants) skin abrasions or photorejuvenation within the previous 12 months~* Any planned facial cosmetic surgery during the study period~* A history of ablative skin resurfacing of the area to be treated during the study.

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Dysport RU 20 U (Type: EXPERIMENTAL): None
- Dysport RU 50 U (Type: EXPERIMENTAL): None
- Dysport RU 75 U (Type: EXPERIMENTAL): None
- Dysport (Azzalure) 50 U (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete